OTCMKTS:AXIM
AXIM Biotechnologies, Inc. Stock News
$0.0139
-0.0001 (-0.714%)
At Close: Jul 03, 2024
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
09:00am, Wednesday, 27'th Mar 2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's
AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
09:00am, Tuesday, 20'th Feb 2024
The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnolo
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
09:00am, Wednesday, 20'th Dec 2023
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays
SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announ
Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
01:36pm, Wednesday, 12'th Jul 2023
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
09:00am, Wednesday, 12'th Jul 2023
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
AXIM Biotechnologies develops test for biomarker of dry eye disease
05:29pm, Tuesday, 08'th Mar 2022 Seeking Alpha
AXIM Biotechnologies (AXIM) said it successfully developed a rapid quantitative tear test for matrix metalloproteinase ((MMP)) MMP-9, an inflammatory biomarker for Dry…
AXIM Biotechnologies (OTCMKTS:AXIM) Shares Up 1.7%
10:50am, Sunday, 21'st Nov 2021 Dakota Financial News
Shares of AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) shot up 1.7% during trading on Friday . The company traded as high as $0.43 and last traded at $0.42. 88,901 shares were traded during mid-day trading, a decline of 55% from the average session volume of 199,137 shares. The stock had previously closed at $0.41. The stocks 50 []
AXIM Biotechnologies Applauds FDA''s Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
04:15pm, Thursday, 18'th Nov 2021 Intrado Digital Media
Companys first rapid test to measure neutralizing antibodies is currently under FDA review Companys first rapid test to measure neutralizing antibodies is currently under FDA review
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
09:00am, Tuesday, 12'th Oct 2021
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting onco
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
09:00am, Monday, 11'th Oct 2021
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
09:00am, Tuesday, 05'th Oct 2021
Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
09:26am, Wednesday, 15'th Sep 2021
Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech
SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting
